WO2005029081A1 - 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 - Google Patents
妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 Download PDFInfo
- Publication number
- WO2005029081A1 WO2005029081A1 PCT/JP2004/014455 JP2004014455W WO2005029081A1 WO 2005029081 A1 WO2005029081 A1 WO 2005029081A1 JP 2004014455 W JP2004014455 W JP 2004014455W WO 2005029081 A1 WO2005029081 A1 WO 2005029081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- toxemia
- pregnancy
- body fluid
- synthase
- fluid sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Definitions
- the present invention provides a method for judging and predicting the severity of preeclampsia, more specifically, a method for simply and objectively determining pregnancy toxemia, and the onset of toxemia in pregnant women who do not exhibit clinical symptoms of preeclampsia. It is a method of predicting the dangers of Furthermore, it is a method to evaluate fetal and placental functions in preeclampsia.
- Toxemia is one of the leading causes of maternal mortality along with bleeding and obstetric pulmonary embolism, and its management and control of hypertension are still important issues for obstetricians.
- the etiology and condition of preeclampsia remain unknown, and there is no uniform definition and classification worldwide.
- pregnancy has at least one or more symptoms of high blood pressure, proteinuria, and edema, and these symptoms are defined as not being just a contingent pregnancy complication.
- the subject is hypertension, and edema alone is not considered toxemia of pregnancy.
- Toxemia of pregnancy is found in about 10% (6-14%) of pregnant women.
- Toxemia of pregnancy is classified into early-onset (onset within 32 weeks) and late-onset (onset after 32 weeks) according to its onset time.
- onset onset within 32 weeks
- late-onset onset after 32 weeks
- hypertension a condition in which hypertension
- proteinuria a condition in which proteins
- edema a condition in which abnormal proteins
- edema a condition in which abnormal proteins
- these symptoms are in the severe range. Things are called severe forms.
- the prognosis is poor due to the rapid deterioration of organ damage in mothers and infants, and strict management is required.
- Diagnosis of preeclampsia is made by examining symptoms of hypertension, proteinuria, and edema. That is, if the systolic blood pressure is 140 mmHg or more and the diastolic blood pressure is 90 mmHg or more, the blood pressure is regarded as hypertension. In addition, 24 hours urine by the Esbach method or a measurement method equivalent thereto,
- Protein urine is detected when 30 mg / dL or more protein is detected. Edema is caused by acupressure Suppose more depression in the tibial crest and weight gain of 500 g or more during the last week of pregnancy. If any of these symptoms are observed, the patient is diagnosed with pregnancy toxemia (Sakamoto, S. et al., Eds. Pregnancy Toxemia. Principle Obstetrics and Gynecology 2: Medical View Inc. 1998: 340-60.).
- plasma protein concentration may be measured because circulating blood volume is reduced and blood concentration is accompanied.
- microthrombi are likely to form, and the coagulation system and secondary fibrinolytic system are in an elevated state, and factors involved in the coagulation-fibrinolysis system such as platelets and] -dimer are also measured.
- lipid and liver function tests are also performed as needed (Shomoto Sakamoto et al., Eds. Pregnancy Toxemia. Principle Obstetrics and Gynecology 2: Medical View Inc. 1998: 340-60.).
- the management and treatment of preeclampsia patients depends on their severity. However, at present, the determination of the severity is performed comprehensively by combining the above-mentioned multiple testing methods, and it is desired to establish a simple and objective method for determining the severity. It is also believed that the effects of pregnancy toxemia, when discovered early, can be significantly reduced by strict management. However, it is difficult to detect early pregnancy toxemia by any of the above-mentioned detection methods, and an index for predicting the onset of pregnancy toxemia has not been established at present.
- Hitoripokarin prostaglandin]) synthase (hereinafter L-PGDS) is an enzyme that catalyzes the isomerization of a common a precursor PG various prostaglandin compounds to PGD 2, transport function of hydrophobic low-molecular-weight (Urade Y. et al., Prostaglandin D synthase: Structure and function. Vitam Horm
- L-PGDS has been reported to be detected at high concentrations in the blood of patients with advanced renal disease (Hoffmann A. et al., Molecular characterization of ⁇ -trace prote in in human serum and urine: Glycobiology 1997; 7: 499-506.) Moreover, the present inventors have found that L-PGDS concentration in body fluids of patients with early renal disease before renal disease progresses. Increase (Hamano K. et al., Blood sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients. Nephron 2002; 92: 77-85.).
- L-PGDS is produced in atherosclerotic plaques, and that L-PGDS levels in body fluids increase in patients with ischemic heart disease (Eguchi Y. et al., Expression of lipocal in-type prostaglandin D synthase (j3-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-94.
- ischemic heart disease Eguchi Y. et al., Expression of lipocal in-type prostaglandin D synthase (j3-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-94.
- Non-Patent Document 1 Hoffmann A. et al., Glycobiology 1997; 7: 499-506
- Non-Patent Document 2 Hamano K. et al., Nephron 2002; 92: 77-85
- Non-Patent Document 3 Eguchi Y. et al., Proc Natl Acad Sci USA 1997; 94:
- An object of the present invention is to provide a method for simply and objectively determining the severity of toxemia of pregnancy, which has been comprehensively determined by various examination means. In addition, by detecting abnormalities before the onset of preeclampsia accurately and with a small burden on the subject, it is impossible to detect pregnancy toxemia by various means of detection for preeclampsia. It is to provide a method for predicting the onset. Another object of the present invention is to provide a method for evaluating fetal and placental functions in preeclampsia.
- the present inventors have conducted intensive studies to solve the above problems, and as a result, measured the concentration of L-PGDS in body fluids such as blood and urine, and used the measured value as an index to determine the severity of preeclampsia. They found that they could do it, and that they could use this measured value as an index to predict toxemia of pregnancy at an early stage, and completed this study.
- the present invention is a method for judging or predicting the severity of toxemia of pregnancy, which comprises measuring L-PGDS in a body fluid sample collected from a subject.
- the present invention is as follows.
- a method for determining the severity of preeclampsia comprising measuring human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject;
- a method for evaluating fetal and placental functions characterized by measuring human ribocalin-type prostaglandin D synthase in a body fluid sample collected from a patient with preeclampsia.
- a kit for detecting toxemia of pregnancy comprising an anti-human lipocalin-type prostaglandin D synthase antibody.
- FIG. 1 shows blood L-PGDS concentrations of normal pregnant women and pregnant women with toxemia before and after 31 weeks of gestation. In all groups, L-PGDS was significantly higher in preeclampsia.
- Figure 2 shows the urinary L-PGDS excretion of normal pregnant women and pregnant women with toxemia before and after 31 weeks of gestation.
- the urine sample was urine as needed, and the measured value was converted to 1 g of urine creatinine.
- L-PGDS was significantly higher in preeclampsia.
- Fig. 3 shows the results of comparing blood L-PGDS concentrations in each group by dividing pregnant women with toxemia of pregnancy at 26 to 38 weeks of gestation into mild or severe types based on clinical symptoms and the like. L-PGDS was significantly higher in severe cases than in mild cases.
- Figure 4 shows that pregnant women with pregnancy toxemia at 26-38 weeks of pregnancy have mild forms based on clinical symptoms and other factors.
- the results of comparison of urinary L-PGDS excretion in each group are shown below. L-PGDS was significantly higher in severe cases than in mild cases.
- Figure 5 shows the results of measuring L-PGDS concentrations in pregnant women with mild or severe pregnancy toxemia based on clinical symptoms, etc., using stored serum collected before the onset of pregnancy toxemia. Is shown. L-PGDS was significantly higher in severe cases than in mild cases.
- Figure 6 shows the measurement of L-PGDS excretion in pregnant women with mild or severe pregnancy toxemia based on clinical symptoms, etc., using preserved urine collected before the onset of pregnancy toxemia. The results are shown. The urine sample was urine as needed, and the measured value was converted to 1 g of creatinine in urine. L-PGDS was significantly higher in severe cases than in mild cases. BEST MODE FOR CARRYING OUT THE INVENTION
- the sample for measuring L-PGDS is a body fluid collected from a subject, and specifically, blood (serum, plasma, etc.), urine (anytime urine, urine collection, etc.), amniotic fluid, cervical mucus, konomiuchi Cavity fluid, fallopian tube lumen fluid and the like.
- blood and urine which are particularly easy to collect, are preferred.
- the subject is a pregnant woman, regardless of the stage of pregnancy (elapsed week after pregnancy), regardless of the stage of pregnancy, and for a pregnant woman who has not yet developed toxemia of pregnancy, according to the method of the present invention.
- the risk of subsequent onset of preeclampsia can be determined, and for pregnant women who already have symptoms of preeclampsia, the severity of preeclampsia can be determined.
- the method for measuring the L-PGDS concentration in the sample is not particularly limited as long as it accurately reflects the L-PGDS concentration. Examples thereof include an immunological assay, an enzyme activity assay, and a capillary assay. Electrophoresis and the like can be mentioned.
- enzyme immunoassay using monoclonal or polyclonal antibodies specific to L-PGDS enzyme immunoassay using monoclonal or polyclonal antibodies specific to L-PGDS, radioimmunoassay It is preferable to use an immunological assay such as a latex agglutination assay, a fluorescence immunoassay assay or the like.
- Monoclonal antibodies include Hypridoma strain 1 B7 (FE thigh BP-5709), 7F5 (FERM BP-5711), and 6F5 (FERM BP-5711).
- Hypri-Doma strain 1 B7 was designated FERM BP-5709 on September 21, 1995 (Original Deposit Date)
- 7F5 was designated FERM BP-5711 on June 6, 1996 (Original Deposit Date).
- 6F5 on September 21, 1995 (Original Deposit Date) as FE BP-5710
- 9A6 on June 6, 1996
- 10A3 on June 6, 1996.
- an L-PGDS detection kit (W097 / 16461) already established by the present inventors may be used as a sandwich ELISA method using a monoclonal antibody.
- early pregnancy toxemia can be detected using the L-PGDS concentration measurement value measured by the above means as an index, and severe pregnancy toxemia can be predicted at an early stage.
- a decrease in placental function in toxemia of pregnancy can be determined using the L-PGDS concentration measurement value measured by the above means as an index.
- the preeclampsia detected by the method of the present invention is not limited to either pure preeclampsia or mixed preeclampsia, and includes eclampsia with cerebral vasospasm attacks. It also includes preeclampsia with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, which causes pulmonary edema, cerebral hemorrhage, premature placental abrasion, and hepatic vasospasm.
- HELLP hemolysis, elevated liver enzymes, and low platelet count
- a cutoff value is first set. For example, measure L-PGDS in a body fluid sample collected from a normal pregnant woman and a pregnant woman who has previously exhibited symptoms of hypertension, proteinuria, or edema and who has been clinically diagnosed with toxemia. . Then, an appropriate L-PGDS cut-off value is set based on the distribution of L-PGDS in normal pregnant women or the diagnostic accuracy such as sensitivity-specificity for detection of toxemia of pregnancy.
- pregnancy toxemia may occur. It can be determined that the person is affected.
- the severity of pregnancy toxemia can be determined by comparing the measured value with each cut-off value. For example, toxemia of pregnancy is divided into severe and mild based on clinical symptoms such as hypertension, proteinuria and edema, and the distribution of L-PGDS in each group and the diagnostic accuracy for determining the severity are determined, and an appropriate cut-off value is set. do it.
- the number of subjects for setting the above cut-off value is limited However, the number is preferably 5 or more, more preferably 10 or more.
- early pregnancy toxemia which cannot be accurately determined only by symptoms such as hypertension, proteinuria, and edema, can be determined.
- the cut-off value in this case is not limited, but the cut-off value for judging whether or not the patient has toxemia is, for example, 50 to 70 ⁇ g / g for blood levels of pregnant women before 31 weeks of gestation. During dL, it can be set between 50 and 60 2 / ( ⁇ for pregnant women after 32 weeks of gestation. In urine concentration, it is 2.7 to 9 mg / g for pregnant women before 31 weeks of gestation It can be set between 3.5 and 7.5 mg / g creatinine for pregnant women after gestational age of 32 weeks, and the cut-off value for judging whether preeclampsia is mild or severe is not limited.
- the blood concentration can be set between 55 and 70/2 / (31 ⁇ , the urine concentration between 4 and 9 mg / g creatinine. If the cut-off value exceeds the cut-off value used for judgment and does not exceed the cut-off value used to determine whether pregnancy toxemia is mild or severe The subject is determined to have mild preeclampsia and if the pregnancy toxin exceeds the cut-off value to determine whether the pregnancy is mild or severe, the subject is deemed to have severe preeclampsia Is determined.
- the method of the present invention determines the risk of developing preeclampsia in a pregnant woman who does not exhibit any symptoms of hypertension, proteinuria, and edema and is considered clinically not suffering from preeclampsia. That is, a method for predicting preeclampsia is also included.
- the concentration of L-PGDS in a body fluid sample collected from a normal pregnant woman is measured, and then the subsequent course of the normal pregnant woman is observed. Separate into groups and pregnant women who developed preeclampsia during pregnancy, and set a cut-off value for prediction between the measured values of the former group and the measured values of the latter group.
- the pregnant woman group is divided according to the time of onset of pregnancy toxemia, the L-PGDS concentration is measured for each group, and a cut-off value is set for each onset period, so that the time of onset of preeclampsia is determined.
- toxemia of pregnancy in the first trimester of pregnancy 15 to 25 weeks Pregnancy toxemia develops early in pregnancy by measuring L-PGDS levels in body fluid samples separately from the group that developed the disease and the group that developed pregnancy toxemia in late pregnancy after 26 weeks of gestation The risk and risk of developing preeclampsia in late pregnancy can be determined.
- L-PGDS concentrations in body fluid samples were measured for pregnant women with mild toxemia and those with severe preeclampsia.
- the risk of developing severe preeclampsia can be determined by setting a force cut-off between the concentration of PGDS and that of L-PGDS before the onset of pregnant women with mild preeclampsia. it can.
- a body fluid sample is collected from a pregnant woman who does not exhibit any symptoms of hypertension, proteinuria, or edema, and the concentration of L-PGDS is measured and compared with the cut-off value for the above-mentioned prediction, thereby causing pregnancy toxicity.
- Determine the risk of developing the disease For example, if the measured value is higher than the power-off value, it is determined that the risk of developing toxemia in the future is high, and if the measured value is lower than the cut-off value, the risk of developing toxemia in the future is low. Is determined. If there is no difference compared to the cut-off value, the judgment is suspended and re-inspection may be performed if necessary.
- the cut-off value in this case is not limited.
- the cut-off value for predicting whether to develop gestational toxemia during pregnancy may be between 55 and 75 g / dL in blood concentration, At medium concentrations, it can be set to 3.0 to 10 mg / g creatinine.
- the cut-off value for predicting whether to develop severe preeclampsia during pregnancy should be between 60 and 75 g / dL for blood concentration and between 5.0 and 75 g for urine concentration. Can be set to 10mg / g creatinine.
- the number of subjects for setting the cut-off value is not limited, but is preferably 5 or more, more preferably 10 or more.
- the present invention provides a method for preparing L- in a body fluid sample collected from a pregnant woman who has developed preeclampsia.
- Methods for assessing fetal and placental function including measuring PGDS.
- the evaluation of the fetus and placental function means that the function of the placenta to supply nutrients and oxygen to the fetus is reduced. Evaluation of whether or not there is any damage to the fetus, such as organ damage.
- the present invention includes a detection reagent or detection kit for toxemia of pregnancy, which comprises an anti-L-PGDS antibody.
- the reagent or the kit may include a carrier having an antibody immobilized thereon, or the antibody may be bound to the carrier in advance.
- the kit may optionally contain a blocking solution, a reaction solution, a reaction stopping solution, a reagent for treating the sample, an instruction sheet describing each cutoff value, or a standard reagent prepared by adjusting the L-PGDS concentration to the cutoff value. May be included.
- the L-PGDS concentration in the body fluid was measured by the sandwich ELISA method as follows.
- an anti-human L-PGDS monoclonal antibody (clone: 7F5) capable of binding to human L-PGDS was diluted with 50 mM carbonate buffer (pH 9.6) to a concentration of 4.4 g / mL.
- the plate was immobilized by adding 300 x L / well to a 96-well microtiter plate and incubating at 4 ° C. Place the plate in phosphate buffered saline (pH
- T-PBS PBS containing Tween20
- antigen solution standard solution or body fluid sample diluted with the blocking solution
- the plate was washed three times with T-PBS, and then diluted with a blocking solution to a concentration of 0.5 g / mL using a horseradish peroxidase-labeled anti-human L-PGDS monoclonal antibody (clone: 1B7). Each well was added and incubated at 30 ° C for 90 minutes.
- the plate was washed three times with T-PBS, and a color developing solution (ABTS solution: Boehringer Mannheim) was added at 100 iL / well, and incubated at 30 ° C. for 30 minutes.
- stop solution (1.5% oxalic acid) was added in IO L / well, and the mixture was stirred with a plate mixer to stop the reaction.
- the absorbance at 405 nm was measured with a commercially available plate reader. Specified.
- Monoclonal antibodies used for the sandwich ELISA can be obtained by injecting a pristane 1. 0 mL intraperitoneally into mice, followed 2 weeks in each antibody-producing cell IX 10 8 pieces of intraperitoneally into mice Two weeks after transplantation, ascites was collected, and the ascites obtained was prepared by subjecting it to a protein A affinity column chromatography operation.
- the cell lines producing the above monoclonal antibodies correspond to the respective monoclonal antibody names, and the respective cell lines were obtained from the Patent Organism Depositary Center, National Institute of Advanced Industrial Science and Technology (Tsukuba Ito, Ibaraki, Japan). 1-chome, No. 1, Central 6), FERM BP-5709 for 1B7 (Original deposit date: September 21, 1995), FERM BP-5711 for 7F5 (Original deposit date: June 6, 1996) Has been deposited as
- Urinary L-PGDS excretion was measured in normal and toxemia pregnant women. Subjects were divided according to the pregnancy stage before 31 weeks of pregnancy and after 32 weeks of pregnancy. At each stage, urine was collected from normal and toxemia-pregnant women. To compensate for differences in urine concentration, urinary L-PGDS excretion was converted to 1 g urine creatinine
- Urinary L-PGDS excretion was measured in pregnant women with toxemia of pregnancy between 26 and 38 weeks of gestation. Subjects were divided into mild and severe preeclampsias based on hypertension, proteinuria, edema and other clinical symptoms, and urinary L-PGDS excretion was compared. The urine sample was urine as needed, and the amount of urinary L-PGDS excreted was converted per 1 g of creatinine in urine (mg / g creatinine). As a result, as shown in Fig.
- L-PGDS Blood levels of L-PGDS were measured in 24 pregnant women who did not develop gestational toxemia at 15 to 25 weeks of gestation, and the presence or absence of gestational toxemia was followed up until delivery. Pregnant The presence or absence of toxicosis was comprehensively determined based on hypertension, proteinuria, edema, and other clinical symptoms. Normal pregnant women shown in Example 1.Blood L-PGDS concentration before the 31st week, which is the 95th percentile value of 61.8 g / dL, was set as the provisional cut-off value. It was classified into two groups, the group exceeding it.
- Urinary L-PGDS excretion was measured in 35 pregnant women without onset of preeclampsia between 15 and 25 weeks of gestation, and the presence or absence of preeclampsia until the delivery was followed. The presence or absence of preeclampsia was comprehensively determined based on hypertension, proteinuria, edema, and other clinical symptoms.
- the urine sample was urine as needed, and the amount of urinary L-PGDS excreted was converted per 1 g of creatinine in urine (mg / g creatinine).
- Normal pregnant woman shown in Example 1.Urine L-PGDS excretion before the 31st week of pregnancy is the 95th percentile value. 4.21 mg / g CLEA Tinin is a provisional cut-off value, and subjects are divided into groups below and above
- a method capable of easily detecting preeclampsia with a small burden on a subject.
- the severity of toxemia of pregnancy which has been comprehensively determined by various examination means, can be simply and objectively determined.
- the method of the present invention can also predict the risk of preeclampsia in pregnant women who do not exhibit clinical symptoms such as hypertension, proteinuria, and edema. Therefore, the method of the present invention is extremely useful for determining and predicting the severity of preeclampsia.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/573,072 US7399596B2 (en) | 2003-09-24 | 2004-09-24 | Method for predicting pregnancy-induced hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003332084A JP3897117B2 (ja) | 2003-09-24 | 2003-09-24 | 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 |
JP2003-332084 | 2003-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005029081A1 true WO2005029081A1 (ja) | 2005-03-31 |
Family
ID=34373061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014455 WO2005029081A1 (ja) | 2003-09-24 | 2004-09-24 | 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7399596B2 (ja) |
JP (1) | JP3897117B2 (ja) |
WO (1) | WO2005029081A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130137122A1 (en) * | 2005-10-13 | 2013-05-30 | Jonathan M. Barasch | Diagnosis and monitoring of chronic renal disease using ngal |
RU2749107C2 (ru) * | 2019-09-13 | 2021-06-04 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Способ раннего прогнозирования фетоплацентарной недостаточности в начале второго триместра беременности |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
WO2014066568A1 (en) * | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
MX2020002788A (es) | 2017-09-13 | 2020-09-14 | Progenity Inc | Biomarcadores de preeclampsia y sistemas y metodos relacionados. |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
RU2743851C1 (ru) * | 2020-03-27 | 2021-02-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО МГМСУ им. А.И. Евдокимова Минздрава России) | Способ диагностики эндотелиальной дисфункции у беременных |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016461A1 (fr) * | 1995-10-31 | 1997-05-09 | Maruha Corporation | Anticorps monoclonal specifique de la prostaglandine d synthetase |
WO1998049559A1 (fr) * | 1997-04-30 | 1998-11-05 | Maruha Corporation | Procede de detection ou de prevision de maladies ischemiques |
JP2000146980A (ja) * | 1998-09-04 | 2000-05-26 | Japan Science & Technology Corp | 腎疾患の検出および病態管理方法 |
JP2000249709A (ja) * | 1999-02-26 | 2000-09-14 | Maruha Corp | 冠血管インターベンション施行後の再狭窄の予測方法 |
JP2001215226A (ja) * | 2000-01-31 | 2001-08-10 | Maruha Corp | 破水の検出方法 |
JP2001220354A (ja) * | 2000-02-04 | 2001-08-14 | Maruha Corp | 頭蓋内出血後の予後改善薬 |
WO2002008756A1 (fr) * | 2000-07-21 | 2002-01-31 | Maruha Corporation | Methode de differenciation de maladies liees a la demence |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4531865A (en) | 1982-07-21 | 1985-07-30 | Tapmatic Corporation | Tapping attachment adapted for numerical computer control |
-
2003
- 2003-09-24 JP JP2003332084A patent/JP3897117B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-24 US US10/573,072 patent/US7399596B2/en not_active Expired - Fee Related
- 2004-09-24 WO PCT/JP2004/014455 patent/WO2005029081A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016461A1 (fr) * | 1995-10-31 | 1997-05-09 | Maruha Corporation | Anticorps monoclonal specifique de la prostaglandine d synthetase |
WO1998049559A1 (fr) * | 1997-04-30 | 1998-11-05 | Maruha Corporation | Procede de detection ou de prevision de maladies ischemiques |
JP2000146980A (ja) * | 1998-09-04 | 2000-05-26 | Japan Science & Technology Corp | 腎疾患の検出および病態管理方法 |
JP2000249709A (ja) * | 1999-02-26 | 2000-09-14 | Maruha Corp | 冠血管インターベンション施行後の再狭窄の予測方法 |
JP2001215226A (ja) * | 2000-01-31 | 2001-08-10 | Maruha Corp | 破水の検出方法 |
JP2001220354A (ja) * | 2000-02-04 | 2001-08-14 | Maruha Corp | 頭蓋内出血後の予後改善薬 |
WO2002008756A1 (fr) * | 2000-07-21 | 2002-01-31 | Maruha Corporation | Methode de differenciation de maladies liees a la demence |
Non-Patent Citations (2)
Title |
---|
MELEGOS, ET AL: "PROSTAGLANDIN D2 SYNTHASE: A COMPONENT OF HUMAN AMNIOTIC FLUID AND ITS ASSOCIATION WITH FETAL ABNORMALITIES", CLINICAL CHEMISTRY, vol. 42, no. 7, 1996, pages 1042 - 1050, XP002903437 * |
SHIKI, ET AL: "CHANGES OF LIPOCALIN-TYPE PROSTAGLANDIN D SYNTHASE LEVEL DURING PREGNANCY", J.OBSTET.GYNAECOL.RES., vol. 30, no. 1, February 2004 (2004-02-01), pages 65 - 70, XP002903436 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130137122A1 (en) * | 2005-10-13 | 2013-05-30 | Jonathan M. Barasch | Diagnosis and monitoring of chronic renal disease using ngal |
US20140377786A1 (en) * | 2005-10-13 | 2014-12-25 | Jonathan Matthew BARASCH | Diagnosis and monitoring of chronic renal disease using ngal |
RU2749107C2 (ru) * | 2019-09-13 | 2021-06-04 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Способ раннего прогнозирования фетоплацентарной недостаточности в начале второго триместра беременности |
Also Published As
Publication number | Publication date |
---|---|
US20070020609A1 (en) | 2007-01-25 |
JP2005098805A (ja) | 2005-04-14 |
US7399596B2 (en) | 2008-07-15 |
JP3897117B2 (ja) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nuutila et al. | Phosphorylated isoforms of insulin-like growth factor binding protein-1 in the cervix as a predictor of cervical ripeness | |
US20100137263A1 (en) | Assay for the detection of biomarkers associated with pregnancy related conditions | |
US20120270747A1 (en) | Method of predicting risk of pre-term birth | |
EP2834638B1 (en) | Methods for diagnosis and prognosis of sepsis | |
JP6639392B2 (ja) | 胎盤成長因子2の選択的測定法 | |
Saleh et al. | The sFlt-1/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort | |
EP2102662A1 (en) | Biomarker for the medicine and the biology of the reproduction | |
EP2883060B1 (en) | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION | |
Tarca et al. | Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study | |
US8846324B2 (en) | In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor | |
JP5926722B2 (ja) | 子癇前症の初期段階マーカーとしてのHbFおよびA1M | |
JP7080176B2 (ja) | 子癇前症におけるマーカーとしてのigfbp-7 | |
JP3897117B2 (ja) | 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 | |
US20190204335A1 (en) | Assay Method For Determining The Risk Of Pre-Eclampsia | |
Spencer et al. | Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction | |
CN108614118B (zh) | 妊娠期高血压疾病相关标志物组合物及其应用 | |
Khalil et al. | How accurate are placental growth factor, urate, lactate dehydrogenase and proteinuria in diagnosing preeclampsia and its severity? | |
WO1999058974A1 (en) | Method and test device for assessing cervical ripeness at term with highly phosphorylated isoforms of igfbp-1 | |
Hassanin et al. | Predictive Value Of Placental Growth Factor In Preeclampsia | |
RU2800716C1 (ru) | Способ прогнозирования риска развития преэклампсии у беременных с сахарным диабетом 2 типа | |
WO2009152601A1 (en) | Use of follistatin-related gene (flrg) as a marker for identifying a fetal abnormality | |
WO2024121392A1 (en) | Multiple sflt-1 measurements for prognosis of early onset preeclampsia | |
AU2022405688A1 (en) | Biomarkers for prognosis of early onset preeclampsia | |
Kostovska et al. | Assessment of urinary podocalyxin as a biomarker of early diagnosis of hypertensive nephropathy | |
JPH10239311A (ja) | 異常分娩の検出方法及び検出試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NA NI NO NZ OM PG PL PT RO RU SC SD SE SG SK SL SY TM TN TR TT TZ UA UG US UZ VC YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007020609 Country of ref document: US Ref document number: 10573072 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10573072 Country of ref document: US |